Androgens and androgen receptor in prostate and ovarian malignancies

被引:15
作者
Meehan, KL [1 ]
Sadar, MD [1 ]
机构
[1] British Columbia Canc Agcy, Dept Canc Endocrinol, Vancouver, BC V5Z 4E6, Canada
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2003年 / 8卷
关键词
androgen receptor; prostate cancer; ovarian cancer; androgen; androgen-regulated genes; Co-activators; interleukin-6; review;
D O I
10.2741/1063
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The molecular and biochemical mechanisms contributing to the development and progression of both prostate and ovarian carcinogenesis are currently unknown. A better understanding of the cross-talk between endocrine, signal transduction and regulatory pathways in normal and neoplastic prostatic and ovarian tissues is necessary to elucidate malignant progression in these tissues. This review compares these two malignancies with reference to androgens and the androgen receptor. In particular, the expression and relevance of androgen-regulated genes are discussed. Cytokines, co-activators and co-regulators that interact or effect the androgen receptor are also considered. With increased understanding of the molecular mechanisms of prostate and ovarian carcinogenesis, the identification and development of novel and existing biomarkers may become more achievable.
引用
收藏
页码:D780 / D800
页数:21
相关论文
共 294 条
[1]   CREB-binding protein in androgen receptor-mediated signaling [J].
Aarnisalo, P ;
Palvimo, JJ ;
Jänne, OA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (05) :2122-2127
[2]  
AbuJawdeh GM, 1996, LAB INVEST, V74, P1105
[3]   Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma [J].
Adler, HL ;
McCurdy, MA ;
Kattan, MW ;
Timme, TL ;
Scardino, PT ;
Thompson, TC .
JOURNAL OF UROLOGY, 1999, 161 (01) :182-187
[4]  
Ahonen MH, 2000, INT J CANCER, V86, P40, DOI 10.1002/(SICI)1097-0215(20000401)86:1<40::AID-IJC6>3.0.CO
[5]  
2-E
[6]   AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968
[7]  
ARASON A, 1993, AM J HUM GENET, V52, P711
[8]   Effect of parathyroid hormone related protein, and dihydrotestosterone on proliferation and ornithine decarboxylase mRNA in human prostate cancer cell lines [J].
Asadi F. ;
Faraj M. ;
Malakouti S. ;
Kukreja S.C. .
International Urology and Nephrology, 2001, 33 (3) :417-422
[9]   Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1β (IL-1β), interleukin-11 (IL-11) and tumour necrosis factor-α (TNF-α) in p53-characterised human ovarian carcinomas [J].
Asschert, JGW ;
Vellenga, E ;
Hollema, H ;
van der Zee, AGJ ;
de Vries, EGE .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (13) :2246-2251
[10]   Ovarian surface epithelium: Biology, endocrinology, and pathology [J].
Auersperg, N ;
Wong, AST ;
Choi, KC ;
Kang, SK ;
Leung, PCK .
ENDOCRINE REVIEWS, 2001, 22 (02) :255-288